MabSelect™ PrismA has been improved with an optimised high-flow agarose base matrix and a genetically engineered protein A-derived ligand, allowing future demands in mAb processing to be met.

• Enhanced dynamic binding capacity allows high mass throughput of processed mAb per resin volume unit
• Excellent alkaline stability enables efficient cleaning and sanitisation using 0,5 to 1,0 M NaOH for improved process economy, bioburden, control and robustness
• Covered by a comprehensive security of supply program, including dual sources of the agarose base matrix and protein A ligand

MabSelect™ PrismA builds on the proven track record of MabSelect™ and MabSelect™ SuRe™ resins in commercial mAb production.